Global Cholera Vaccine Market is valued at USD 110.7 Million in 2021 and is expected to reach USD 257.2 Million by 2028 with a CAGR of 12.8% over the forecast period.
Global Cholera Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of cholera and rising investment in this field are some of the major factors driving the growth of the Global Cholera Vaccine Market.
Cholera is an intestinal infection caused by bacterial contaminations that spread through contaminated food and water. Its indications include; severe diarrhea, dehydration, abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is currently a global threat to public health, which can be prevented through the vaccine. The cholera vaccine exposes a minor dose of live cholera bacteria in the body that helps grow immunity against the disease. It can be given orally or injected intradermally or intramuscularly in the body.
The Covid-19 outbreak has slightly affected on the cholera virus vaccine market in the year 2020. Due to, strict lockdown measures and social distancing norms across the globe. Due to the unbreakable spread and increasing, death rate governments are trying to conquer the situation due to that pharmaceutical companies rushed towards the research and development and production of coronavirus vaccine. Due to this, production of cholera virus is slightly affected. Despite of, number of cholera vaccines are under clinical trial phases.
The cholera vaccine market is segmented on the basis of product, end-user and region & country level. On the basis of product, the global cholera vaccine market is segmented into dukoral, shanchol, vaxchora, euvichol and euvichol-plus, others. On the basis of end-user, the global cholera vaccine market is segmented into hospitals & clinics, research & academic laboratories, and others.
The regions covered in this cholera vaccine market report are Asia-Pacific, North America, Europe, and the Rest of the World. Based on a country level, the market of cholera vaccine is subdivided into the U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
On June 10th, 2016; The U.S. Food and Drug Administration approved Vaxchora, a vaccine for the prevention of cholera caused by serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas. Vaxchora is the only FDA-approved vaccine for the prevention of cholera.
Cholera is one the most widespread epidemic infectious diseases caused by the bacterium vibrio cholera. It causes severe watery diarrhea requiring immediate treatment as it may lead to death. According to the European Centre for Disease Prevention and Control (ECDPC), on November 23rd, 2021, ~13,162 assumed cholera cases, including 101 deaths, have been reported worldwide. Moreover, according to the WHO, Scientists have estimated that every year there are 1.3 to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to cholera. Thus, the increasing cases of Cholera is one of the major factors fostering the demand for Cholera vaccine.
In addition, cholera is caused by the ingestion of contaminated food and water. Hence, deficiency of proper sanitation and clean water upsurges the risk of people suffering from cholera. According to the WHO, approximately 600 million nearly one in 10 people in the world fall ill after eating contaminated food and 420, 000 die every year, causing in the loss of 33 million well life years. Also, according to the WHO; contaminated drinking water is estimated to cause 485,000 diarrheal deaths each year. Additionally, according to the data from the Ministry of Public Health and Population, October 2010 to December 2018, 819,000 people showed signs of the disease and 9,700 died, making Haiti one of the country’s greatest severely impacted by cholera.
However, maximum price of cholera vaccine resultant in unaffordability for patients in the developing and under-developed economies may hinder the market growth. In spite of that, increasing number of research and development activities in this field may create more opportunities for the further growth of the market.
Geographically, North America is expected to show the fastest growth in the global Cholera Vaccine market. Several government programs such as oral cholera vaccination campaigns, the number of people traveling to countries with sudden outbreaks of cholera is increasing and demand for immunization is growing. In the U.S. Food and Drug Administration (FDA) approved Vaxchora, a vaccine for the prevention of cholera affected by serogroup O1 in adults 18 through 64 years of age migrant to cholera-affected areas. Vaxchora is the FDA-agreed vaccine for the prevention of cholera. According to the (center and disease control and prevention) CDC, Vaxchora had described to reduce the chance of severe diarrhea in people by 90% at 10 days after vaccination and by 80% at 3 months later vaccination.
Asia Pacific is expected to show a significant growth in the global Cholera vaccine market owing to the increasing cases of Covid-19, rising awareness and growing investment in this field in this region.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 110.7 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 257.2 Million|
|Tables, Charts & Figures:||175|
|Key Players / Companies||AstraZeneca, Shantha Biotechnics Private Limited, Valneva SE, Merck & Co. Inc., PaxVax Inc. and others.|
|Segments Covered||By Product, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|